⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
COCP News
Cocrystal Pharma, Inc. Common Stock
Form 8-K
sec.gov
COCP
Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026
globenewswire.com
COCP
Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus
globenewswire.com
COCP
Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference
globenewswire.com
COCP
Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
globenewswire.com
COCP
Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules
globenewswire.com
COCP
Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program
globenewswire.com
COCP
Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference
globenewswire.com
COCP